A blood based 12-miRNA signature of Alzheimer disease patients.
Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stähler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A. · 2013
Read A blood based 12-miRNA signature of Alzheimer disease patients. by Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stähler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4053778.txt.
Introduction
Petra Leidinger and colleagues build a blood test signature for Alzheimer's disease from twelve small RNAs, in Genome Biology in 2013. Alzheimer's is the commonest dementia, yet early, gentle diagnosis still lacks a reliable marker. Small RNAs in blood shift with disease and can be measured without touching the brain.
Sequencing blood from patients and healthy controls found well over a hundred small RNAs at changed levels. The team picked twelve and rechecked them in a larger set of two hundred samples. That set added look-alike brain diseases and a mild impairment stage. The dozen separated Alzheimer's from healthy controls with accuracy above ninety percent. Telling it apart from other brain diseases was harder but still workable. The targets of the twelve point to nerve development and wiring. The authors propose blood small RNAs as a practical route toward earlier, kinder diagnosis.
Catalog record
| CREATOR | Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stähler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A blood based 12-miRNA signature of Alzheimer disease patients By Petra Leidinger, Christina Backes, Stephanie Deutscher, Katja Schmitt, Sabine C Mueller, Karen Frese, Jan Haas, Klemens Ruprecht, Friedemann Paul, Cord Stähler, Christoph JG Lang, Benjamin Meder Published in: Genome Biology DOI: 10.1186/gb-2013-14-7-r78 ABSTRACT Abstract Background Alzheimer disease (AD) is the most common form of dementia but the identification of reliable, early and non-invasive biomarkers remains a major challenge. We present a novel miRNA-based signature for detecting AD from blood samples. Results We apply next-generation sequencing to miRNAs from blood samples of 48 AD patients and 22 unaffected controls, yielding a total of 140 unique mature miRNAs with significantly changed expression levels. Of these, 82 have higher and 58 have lower abundance in AD patient samples. We selected a panel of 12 miRNAs for an RT-qPCR analysis on a larger cohort of 202 samples, comprising not only AD patients and healthy controls but also patients with other CNS illnesses. These included mild cognitive impairment, which is assumed to represent a transitional period before the development of AD, as well as multiple sclerosis, Parkinson disease, major depression, bipolar disorder and schizophrenia. miRNA target enrichment analysis of the selected 12 miRNAs indicates an involvement of miRNAs in nervous system development, neuron projection, neuron projection development and neuron projection morphogenesis. Using this 12-miRNA signature, we differentiate between AD and controls with an accuracy of 93%, a specificity of 95% and a sensitivity of 92%. The differentiation of AD from other neurological diseases is possible with accuracies between 74% and 78%. The differentiation of the other CNS disorders from controls yields even higher accuracies. Conclusions The data indicate that deregulated miRNAs in blood might be used as biomarkers in the diagnosis of AD or other neurological diseases. Keywords: Alzheimer disease, miRNA, biomarker, next-generation sequencing, quantitative Real Time PCR BACKGROUND Alzheimer disease(AD) is the most common form of neurodegenerative illness leading to dementia which is predicted to affect as much as 1 in 85 people globally by 2050 [1]. While early-onset (familiar) AD has been reported in younger people, the majority of (sporadic) AD cases is diagnosed in people aged over 65 years [2]. As of today, final diagnosis of AD can only be achieved by autopsy making the identification of reliable, early, and non-invasive biomarkers a major challenge. Finding such non-invasive, reliable diagnostic tools is of paramount importance as it appears that early intervention in the prodromal stage of AD or the identification and therapy of those patients with mild cognitive impairment who will transform to AD rapidly might be a possibility to delay the onset of AD substantially [3]. A prominent example of recently developed AD biomarker assays is the combinatorial analysis of the concentration of peptides and proteins: beta-amyloid-1-42 (Aß 42), tau, and/or p-tau in the cerebrospinal fluid (CSF). According to the S3 guidelines, an increased level of tau protein together with a decreased level of beta-amyloid-1-42 provides strong evidence for the presence of AD [4]. The combinatorial analysis of all three factors yields even higher diagnostic accuracy than the combination of only two of the above-mentioned proteins [5]. Furthermore, combinatorial analysis of Aß levels and tau levels can discriminate between patients with stable mild cognitive impairment (MCI) and patients with progressive MCI into AD or other types of dementia with a sufficient diagnostic accuracy [6]. Nevertheless, according to the S3 guidelines, the analysis of CSF biomarker is only indicated to confirm the diagnosis if other clinical symptoms give evidence for the presence of neurodegenerative dementia or for the differential diagnostics of other forms of diseases that can cause symptoms like dementia (encephalitis, neuroborreliosis, multiple sclerosis, Lues, brain abscess, metastases). The use of peripheral markers, like Aß and tau in easily accessible peripheral cells (in particular platelets and skin fibroblasts), as a diagnostic tool has been under investigation for more than 10 years [7,8]. Molecular genetics analyses of common single nucleotide polymorphisms (SNPs) in genes such as presenilin or ApoE4 did not significantly improve risk estimation for the susceptibility of AD [9]. Likewise, there is no consistent evidence for an association between AD and genetic variation of mitochondrial DNA (mtDNA) [10]. There is increasing effort to develop molecular diagnostic markers that meet requirements like easy accessibility, for example, from blood, sufficiently high specificity and sensitivity, low costs and applicability by laboratories with standard equipment. Several blood, plasma, or serum born AD biomarkers have been proposed to meet these criteria. Doecke et al. recently presented a panel of protein biomarkers to reliably detect AD with an accuracy of 85% [11]. Moreover, Tan et al. provided evidence that the proteins p53 and p21 can be used to detect AD using blood samples. A receiver operating characteristic curve analysis revealed a specificity of 76% and a sensitivity of 84% for p53, 88% and 82% for p53(ser15), 80% and 75% for p21, and 84% and 68% for p21(thr145) [12]. Besides proteins microRNAs (miRNAs) have also demonstrated their potential as non-invasive biomarkers from blood and serum for a wide variety of human pathologies [13]. A deregulation of miRNA expression might be involved in neurological dysfunction or neurodegenerative processes. Interestingly, Liang et al. [14] showed that the expression pattern of brain and blood PBMC cluster together which might be an indication that a specific blood based expression signature might prove to be useful as biomarker for AD and other neurological diseases. MiRNA expression analyses can be readily applied for in vitro diagnostic testing by molecular diagnostics and CLIA (Clinical Laboratory Improvement Amendments) laboratories. While altered miRNA patterns have been exhaustively investigated in AD patients' tissue samples or cell cultures [15-18], less information on circulating miRNAs in AD is known. A recent serum profiling of AD patients provided first evidence that expression changes of circulating miRNAs may be valuable biomarkers for AD [19]. We describe our results obtained by applying the next-generation sequencing (NGS) approach to screen the expression of all human miRNAs in blood from extensively characterized AD patients and healthy controls. Patient blood was obtained from the SAMPLE (Serial Alzheimer diseaseand MCI Prospective Longitudinal Evaluation) Registry of PrecisionMed (San Diego, CA, USA) and blood from age-matched healthy donors from the ACE (Aging Cognition Evaluation) Registry, a PrecisionMed- UBC (The University of British Columbia) collaboration. We identified 140 unique differentially expressed miRNAs between AD patients and controls. Validation of a 12-miRNA signature was carried out by RT-qPCR in a cohort of 202 samples encompassing patients suffering from other neurological disorders including mild cognitive impairment as a potential preliminary stage of AD, and other neurodegenerative diseases like Parkinson disease and multiple sclerosis as well as mental diseases like schizophrenia (SCHIZ), major depression (DEP), and bipolar disorder (BD). A combination of AD-specific miRNA expression signatures with the rapidly developing and expanding amyloid load imaging techniques may be useful as non-invasive diagnostic tools in AD diagnosis in the future [20]. RESULTS Initial biomarker screening using next-generation sequencing To detect potential AD biomarkers we examined blood from well-characterized patients and controls. We obtained blood from the SAMPLE (Serial Alzheimer diseaseand MCI Prospective Longitudinal Evaluation) Registry of PrecisionMed (San Diego, CA, USA). SAMPLE is a sample depository resulting from a longitudinal study that evaluates cognition in women and men, who are recruited, evaluated, cognitively